Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)
Status:
Terminated
Trial end date:
2020-05-05
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo-controlled, multicentre, multinational,
prospective study in patients with operable chronic thromboembolic pulmonary hypertension
(CTEPH) prior to pulmonary endarterectomy (PEA) with high preoperative pulmonary vascular
resistance (PVR). Patients will be randomised in a 1:1 ratio to receive riociguat or matching
placebo for 3 months before undergoing PEA. The primary objective of this study is to assess
the efficacy of riociguat on preoperative PVR compared to placebo in patients with operable
CTEPH.